Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 828-831

  Idilman, Ramazan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

3TC; Antiviral; Hepatitis B virus

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; FAMCICLOVIR; GANCICLOVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG;

ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PROPHYLAXIS; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARRIER STATE; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HUMANS; LAMIVUDINE; TIME FACTORS; VIRUS ACTIVATION;

EID: 21244443465     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki114     Document Type: Article

References (24)

1. Lee, W. M. (1997). Hepatitis B virus infection. N Engl J Med 337, 1733-45.
2. Maddrey, W. C. (2000). Hepatitis B. An important public health issue. J Med Virol 61, 362-6.
3. Ustün, C., Koc, H., Karayalcin, S. et al (1997). Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 20, 289-96.
4. Lau, G. K. K., He, M., Fong, D. Y. T. et al. (2002). Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36, 702-9.
5. Locasciulli, A., Alberti, A., de Bock, R. et al. (1994). Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe. Bone Marrow Transplant 14, 833-7.
6. Fattovich, G., Brollo, L., Giustina, G. et al. (1991). Natural history and prognostic factors for chronic hepatitis type B. Gut 32, 294-8.
7. Papatheodoridis, G. V., Dimou, E. & Papadimitropoulos, V. (2002). Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 97, 1618-28.
8. Dienstag, J. L., Schiff, E. R., Wright, T. L. et al. (1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341, 1256-63.
9. Hoofnagle, J. H., Dusheiko, G. M., Schafer, D. F. et al. (1982). Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96, 447-9.
10. Steinberg, J. L., Yeo, W., Zhong, S. et al. (2000). Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: precore/core mutations may play an important role. J Med Virol 60, 249-55.
11. Yeo, W., Chan, P. K. S., Zhong, S. et al. (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J Med Virol 62, 299-307.
12. Tur-Kaspa, R., Burk, R. D., Shaul, Y. et al. (1986). Hepatitis B virus contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83, 1627-31.
13. McMillan, J. S., Shaw, T., Angus, P. W. et al. (1995). Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22, 36-43.
14. Rossi, G. (2003). Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leukemia and Lymphoma 44, 759-66.
15. Rossi, G., Pelizzari, A., Motta, M. et al. (2001). Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115, 58-62.
16. Lim, L. L., Wai, C. T., Lee, Y. M. et al. (2002). Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 16, 1939-44.
17. Shibolet, O., Ilan, Y., Gillis, S. et al. (2002). Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100, 391-6.
18. Idilman, R., Arat, M., Soydan, E. et al. (2004). Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepatitis 11, 141-7.
19. Lau, G. K. K., Liang, R., Wu, P. C. et al. (1998). Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 28, 359-68.
20. Ahmed, A. & Keeffe, E. B. (1999). Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B infection. Am J Gastroenterol 94, 249-51.
21. Uchida, N., Gondo, H., Himeji, D. et al. (2000). Lamivudine therapy for a hepatitis B surface antigen positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 26, 1243-5.
22. Cainelli, F., Longhi, M. S., Concia, E. et al. (2001). Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 96, 1651-2.
23. Chan, T. M., Fang, G. X., Tang, C. S. O. et al. (2002). Preemptive lamivudine therapy based on HBV-DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36, 1246-52.
24. Qaqish, R. B., Mattes, K. A. & Ritchie, D. J. (2003). Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Therap 25, 3084-99.